Plain-English translation of NCT04565483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing a medication called Benralizumab in people with severe asthma that hasn't been controlled with standard treatments. The trial aims to understand which patients respond best to this medication and how early blood tests might predict who will benefit most. Researchers will follow participants for 16 months while they receive the medication.
Severe asthma can be very difficult to control even with high-dose steroids and other standard treatments. This medication targets a specific type of immune cell involved in some people's asthma. By understanding which patients benefit most, doctors can better decide who should receive this treatment and predict treatment success earlier.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication at your first visit and then at 1, 2, 4, 6, 8, 10, and 12 months—eight injections total over one year. You'll have in-person clinic visits and phone check-ins, with about 6 on-site visits over the 16-month study period. Researchers will monitor your asthma control, track how many flare-ups you have, and take blood samples to study which patients respond best to the medication.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France